Proteomics International Laboratories Ltd (PIQ.AX) Stock Analysis
A CAP-accredited, Medicare-priced predictive diagnostics platform with massive upside—if PIQ can survive the cash runway and convert reimbursement into real test volumes.
Overview
Proteomics International Laboratories (PIQ.AX) is a Perth-based precision diagnostics company commercializing its proprietary Promarker proteomics platform to predict disease progression years before symptoms. The company historically relied on accredited analytical services (ISO 17025) and partnerships, but its late-2025/early-2026 pivot is toward direct diagnostic commercialization—especially in the U.S.—by operating its own CLIA-certified, CAP-accredited reference laboratory in Irvine. This shift is intended to replace low-margin royalties with full test economics (notably Medicare reimbursement of US$390.75 for PromarkerD). The core portfolio includes PromarkerD for diabetic kidney disease risk prediction, PromarkerEso for esophageal adenocarcinoma rule-out, PromarkerEndo for non-invasive endometriosis diagnosis, and OxiDx for oxidative stress monitoring. The investment rests on whether PIQ can translate reimbursement and accreditation milestones into scaled test volumes before cash constraints force dilutive funding.